Sales of Anticoagulant Reversal Drugs to Soar in North America, While APAC Sees Moderate Growth
Favourable regulatory scenario, especially in developed economies of North America and Europe, has inadvertently created a highly conducive environment for the growth of the anticoagulant reversal drugs market.
However, steep prices of anticoagulant reversal drugs will result in moderate sales in price-sensitive countries of APAC and MEA.
Taking a cue from this high-cost concern, regional and local players are looking at increasing their presence in the anticoagulant reversal drugs market through the introduction of generic drugs.
Their global counterparts, however, are increasing investments towards the development of blockbuster drugs.
All-in-all, the anticoagulant reversal drugs market is projected to offer equal growth opportunities to global, regional, and local players, given the fragmented nature of the market space.
Popularity of Idarucizumab to Lose Vigour to Andexxa
Sales of Idarucizumab increased 19% Y-o-Y in 2019 over 2018. However, according to the estimation of a seasoned analyst at Fact.MR, year-over-year sales of the same drug will witness a sharp decrease of 11% in 2026 over 2025.
This drug achieved immediate traction in the anticoagulant reversal drugs market, owing to the absence of an equivalent reversal agent.
The downward sales curve traced by Idarucizumab can be attributable to the increasing popularity of Andexxa, which received approval from the U.S. Food and Drug Administration in 2018.
There has been a steep increase in the preference for Andexxa over Idarucizumab, given the recognition received by the novel reversal agent as an orphan drug.
In the future, the popularity of this drug is projected to witness exponential growth, as there is an absence of effective drugs in the anticoagulant reversal drugs market.
Know More Details About the Report
Introduction of New Technology Add-on Payment to Underpin Sales
As the challenge regarding the limited penetration of effective drugs came into light, cost-prohibitive nature of reversal agents was found to have a negative influence on their sales.
Governments of developed countries launched a new payment system - new technology add-on payment (NTAP) - to promote the adoption of new and expensive drugs.
The reimbursement plan, in turn, is projected to underpin the expenses of patients and drive profitability to the anticoagulant reversal drugs market during the forecast period.
Under this plan, the Praxbind drug is eligible for availing complete reimbursement in England, Wales, and Ireland, without the need for full approval by Health Technology Appraisal authorities.
On the backdrop of favourable reimbursement plans present in the anticoagulant reversal drugs market, a wide base of patients is expected to avail these benefits, and, in turn, amplify sales prospects.
Market Players Strive to Meet Unmet Clinical Demands
The application of reversal agents has witnessed a marked increase in recent times, in life-threatening conditions or cases with uncontrolled bleeding.
Manufacturers in the anticoagulant reversal drugs market are sensing a rise in demand and navigating their research & development endeavours to bridge the underlying gaps present in these therapeutics.
This is leading to a robust pipeline for anticoagulant reversal drugs, especially in Europe and North America, given the high concentration of leading players in these regions.
In addition, there has been an increase in governments’ financial aid towards promoting the production of effective therapeutics, which is further paving way for the introduction of novel drugs in the anticoagulant reversal drugs market.
Fast-track approval of blockbuster drugs is enabling players in the anticoagulant reversal drug market to achieve faster time-to-market, which is predicted to extend the scope of the market.
Avail customized purchase options for your needs
Sales through Hospital Pharmacies will Remain High in North America
The evolving landscape is adding new revenue streams for the anticoagulant reversal drugs market; however, hospital pharmacies are projected to account for ~65% of the total sales by 2026.
The increasing prevalence of atrial fibrillation, intracranial haemorrhages, and gastrointestinal haemorrhages is projected to boost the demand for anticoagulant reversal drugs.
North America is expected to close a majority of sales through anticoagulant reversal drugs. The region is home to a large number of hospitals offering quality healthcare services.
With the growing number of surgeries, the sales of anticoagulant reversal drugs through hospital pharmacies are on the rise. In addition, recent times have witnessed a surge in the number of outpatient care centres and ambulatory surgical centres, which is projected to strengthen the demand for anticoagulant reversal drugs.
Anticoagulant Reversal Drugs Market - Assessment of Key Segments
Authors of the report have segmented the anticoagulant reversal drugs market into key categories in order to study the market at a microscopic level. The key segments considered while bifurcating the anticoagulant reversal drugs market include:
Besides magnifying focus on the crucial segments, this exclusive study also offers information on the anticoagulant reversal drugs market at a country level, to identify the underlying opportunities available for players in the anticoagulant reversal drugs market for the forecast period. Among all the estimated data, the report also includes Y-o-Y growth projections, which can help market players in comprehending the precise trajectory at which the anticoagulant reversal drugs market has been growing.
Anticoagulant Reversal Drugs Market - Scope of the Study
The study on the anticoagulant reversal drugs market is an exclusive report published by Fact.MR, which provides information regarding the key growth influencers of the landscape. This study offers insights on the growth of the anticoagulant reversal drugs market, by analysing the historical data for the period of 2016 - 2019, and 2020 - 2026 as the forecast period.
Estimation of the revenue of the anticoagulant reversal drugs market has been carried out in terms of value (US$ Mn). This exclusive report focuses on offering information on the key trends that are likely to influence the growth of the anticoagulant reversal drugs market, in addition to crucial microscopic and macroeconomic growth indicators.
The incisive report offers the key dynamics, along with their influence on the value chain, which is projected to positively impact the future growth of the anticoagulant reversal drugs market.
The study also includes a detailed section dedicated to impeders that could challenge the growth of players in the anticoagulant reversal drugs market. The report unfolds profitable opportunities for market players, which can be leveraged to consolidate their position in the global market.
With a view of aiding stakeholders in the anticoagulant reversal drugs market, the study includes a detailed section on the competition landscape of the anticoagulant reversal drugs market.
The study provides a dashboard view of the report, with a detailed comparison of players operating in the anticoagulant reversal drugs market, based on total revenue, market presence, and key developments. In addition to this, key strategies and recent developments implemented by players in the anticoagulant reversal drugs market have also been included in this comprehensive study.
Key companies profiled in the anticoagulant reversal drugs market include Perosphere Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Portola Pharmaceuticals, Inc., CSL Limited, Octapharma AG, Amneal Pharmaceuticals Inc., Bausch Health Companies, Inc., Fresenius Kabi AG, and Pfizer, Inc.
Anticoagulant Reversal Drugs Market - Research Methodology
The anticoagulant reversal drugs market has been evaluated by taking a top-down and bottom-up approach. Demand, geographical presence, distribution strategies by manufacturers, and initiatives taken by governments and NGOs are various factors considered while estimating the revenue of the anticoagulant reversal drugs market, and thus, reaching global numbers.
The study on the anticoagulant reversal drugs market is further validated through extensive primary research on the data extracted from exhaustive secondary research.
In order to conduct secondary research, annual company reports, company websites, data from the World Health Organization (WHO), SEC filings, press releases, investor presentations, and other similar resources were studied. Both, the top-down and bottom-up approaches were undertaken by analysts of the report to find accurate data regarding the growth of the anticoagulant reversal drugs market.
To validate the information compiled through secondary research, interviews with key opinion leaders and subject matter experts were scheduled. The analysis aims at studying the business environment, unmet needs of consumers, key restraints, historical sales pattern, and investment landscape.
In addition to this, authors of the report also had email and telephonic interactions with the senior management of leading and prominent companies to confirm the size, growth trends, and future outlook of the anticoagulant reversal drugs market.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.